Pfizer: FDA approves male breast cancer drug

(CercleFinance.com) - The US Food and Drug Administration has approved Pfizer's drug to treat men with advanced or metastatic breast cancer, who currently have limited treatment options.


The FDA has approved a supplemental new drug application (sNDA) to expand the indications for Ibrance, in combination to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, Pfizer said.

Ibrance is an oral inhibitor of key regulators of the cell cycle that triggers cellular progression.

Copyright (c) 2019 CercleFinance.com. All rights reserved.